Pubblicazioni

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.

Cinti F, Moffa S, Impronta F, Cefalo CM, Sun VA, Sorice GP, Mezza T, Giaccari A.

Drug Des Devel Ther. 2017 Oct 3;11:2905-2919. doi: 10.2147/DDDT.S114932. eCollection 2017. Review. PMID:29042751

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.

Pirillo A, Garlaschelli K, Arca M, Averna M, Bertolini S, Calandra S, Tarugi P, Catapano AL; LIPIGEN Group.

Atheroscler Suppl. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosissup.2017.07.002.

PMID:28965616

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).

Averna M, Cefalù AB, Casula M, Noto D, Arca M, Bertolini S, Calandra S, Catapano AL, Tarugi P; LIPIGEN Group.

Atheroscler Suppl. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosissup.2017.07.001.

PMID: 28965615

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.

Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H.

Diabetes Obes Metab. 2017 Sep 1. doi: 10.1111/dom.13105. [Epub ahead of print]

PMID: 28862801

Nuclear Export of FoxO1 Is Associated with ERK Signaling in β-Cells Lacking Insulin Receptors.

Mezza T, Shirakawa J, Martinez R, Hu J, Giaccari A, Kulkarni RN.

J Biol Chem. 2016 Oct 7;291(41):21485-21495. Epub 2016 Aug 17.

PMID: 27535223

β-Cell Glucose Sensitivity Is Linked to Insulin/Glucagon Bihormonal Cells in Nondiabetic Humans.

Mezza T, Sorice GP, Conte C, Sun VA, Cefalo CM, Moffa S, Pontecorvi A, Mari A, Kulkarni RN, Giaccari A.

J Clin Endocrinol Metab. 2016 Feb;101(2):470-5. doi: 10.1210/jc.2015-2802. Epub 2015 Dec 9.

PMID: 26649619

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.

Fioretto P, Giaccari A, Sesti G.

Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x. Review.

PMID: 26474563

Peroxiredoxin 6, a novel player in the pathogenesis of diabetes.

Pacifici F, Arriga R, Sorice GP, Capuani B, Scioli MG, Pastore D, Donadel G, Bellia A, Caratelli S, Coppola A, Ferrelli F, Federici M, Sconocchia G, Tesauro M, Sbraccia P, Della-Morte D, Giaccari A, Orlandi A, Lauro D.

Diabetes. 2014 Oct;63(10):3210-20. doi: 10.2337/db14-0144. Epub 2014 Jun 19.

PMID:24947358

Insulin resistance alters islet morphology in nondiabetic humans.

Mezza T, Muscogiuri G, Sorice GP, Clemente G, Hu J, Pontecorvi A, Holst JJ, Giaccari A, Kulkarni RN.

Diabetes. 2014 Mar;63(3):994-1007. doi: 10.2337/db13-1013. Epub 2013 Nov 11.

PMID: 24215793

Genetic disruption of SOD1 gene causes glucose intolerance and impairs β-cell function.

Muscogiuri G, Salmon AB, Aguayo-Mazzucato C, Li M, Balas B, Guardado-Mendoza R, Giaccari A, Reddick RL, Reyna SM, Weir G, Defronzo RA, Van Remmen H, Musi N.

Diabetes. 2013 Dec;62(12):4201-7. doi: 10.2337/db13-0314. Epub 2013 Sep 5.

PMID:24009256

Servizi

Inquadramento diagnostico - terapeutico delle principali patologie endocrine e metaboliche.

Le ultime news

UOC Endocrinologia e Malattie del Metabolismo (direttore prof. Alfredo Pontecorvi)

Centro per le Malattie Endocrine e Metaboliche (responsabile prof. Andrea Giaccari)

Fondazione Policlinico Universitario A. Gemelli - Roma

EMAIL

diabete@policlinicogemelli.it
colesterolo@policlinicogemelli.it
endocrinologia@policlinicogemelli.it

L'esperto risponde

 

Fai la tua domanda